id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-348855-lnltoj1n	Iannaccone, Giulia	Weathering the Cytokine Storm in COVID-19: Therapeutic Implications	2020-06-29		.txt	text/plain	4669	207	37	The exaggerated cytokine release in response to viral infection, a condition known as cytokine release syndrome (CRS) or cytokine storm, is emerging as the mechanism leading to ARDS and MOF in COVID-19, thus endorsing the hypothesis that properly timed anti-inflammatory therapeutic strategies could improve patients' clinical outcomes and prognosis. CS are the cornerstone of treatments for cytokine storms and macrophage activation syndrome in autoimmune/autoinflammatory diseases [18] ; in the COVID-19 scenario they may be useful in the more severe forms of CRS to curb the systemic inflammatory response and prevent the occurrence of ARDS, if appropriately timed [10, 19] , 20]. Tocilizumab is now already included in many practice guidelines for COVID-19 management, especially for the treatment of critically ill patients with severe refractory hypoxemia in a later stage after the high-viral-load initial phase all over the world, while we wait for more definite data from multiple ongoing clinical trials [42] .	./cache/cord-348855-lnltoj1n.txt	./txt/cord-348855-lnltoj1n.txt